Technology

AddToAny

Google+ Facebook Twitter Twitter

UK biomedical catalyst award

Centauri Therapeutics Ltd, a biotechnology company focused on the treatment of infectious diseases and cancer, has been awarded up to £945,000 under Innovate UK’s Biomedical Catalyst programme.

Alongside backing from the Company’s investors, this award from the UK’s innovation agency will co-fund research focused on antimicrobial resistance. The project aims to generate a clinical candidate drug against Gram-negative bacteria, which are a major cause of mortality in hospital-acquired pneumonias.

centauritherapeutics.com

Related Articles

The new dawn of immunotherapy

Steven Rosenberg made headlines around the globe for a breakthrough that could make immunotherapy a frontline cancer treatment.

Vaccine to treat lung cancer

A first-of-its-kind treatment vaccine has moved into a phase I clinical trial for patients with non-small cell lung cancer.

Journal-based learning: iStock

July: Journal-based learning

Each article’s contents should be read, researched and understood, and you should then come to a decision on each question. The pass mark is 17 out of 20 questions answered correctly. JBL exercises may be completed at any time until the published deadline date. Please select your choice of correct answers and complete the exercises online at: www.ibms.org/cpd/jbl

Could bacteriophages replace antibiotics?

A small-scale preliminary trial concludes that bacteriophages could be a viable replacement for antibiotics in the future.

Top